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T-705 (favipiravir) is a new antiviral agent in advanced clinical development for influenza therapy. It is supposed to act as an
alternative substrate for the viral polymerase, causing inhibition of viral RNA synthesis or virus mutagenesis. These mechanisms
were also proposed for ribavirin, an established and broad antiviral drug that shares structural similarity with T-705. We here
performed a comparative analysis of the effects of T-705 and ribavirin on influenza virus and host cell functions. Influenza virus-
infected cell cultures were exposed to T-705 or ribavirin during single or serial virus passaging. The effects on viral RNA synthe-
sis and infectious virus yield were determined andmutations appearing in the viral genome were detected by whole-genome
virus sequencing. In addition, the cellular nucleotide pools as well as direct inhibition of the viral polymerase enzyme were
quantified. We demonstrate that the anti-influenza virus effect of ribavirin is based on IMP dehydrogenase inhibition, which
results in fast and profound GTP depletion and an imbalance in the nucleotide pools. In contrast, T-705 acts as a potent and
GTP-competitive inhibitor of the viral polymerase. In infected cells, viral RNA synthesis is completely inhibited by T-705 or
ribavirin at >50M, whereas exposure to lower drug concentrations induces formation of noninfectious particles and accumu-
lation of random point mutations in the viral genome. This mutagenic effect is 2-fold higher for T-705 than for ribavirin. Hence,
T-705 and ribavirin both act as purine pseudobases but profoundly differ with regard to the mechanism behind their antiviral
andmutagenic effects on influenza virus.
The global burden of influenza is estimated at 250,000 to500,000 deaths per year (1). On a global average, influenza A
virus accounts for75%of seasonal infections; the other25% is
caused by influenza B virus (2). In addition, zoonotic influenza A
viruses of swine or avian species create a risk for pandemics, such
as occurred in 2009 (3). Influenza vaccination is a highly effective
preventive measure, yet it suffers from some limitations: unsatis-
factory immune response in elderly or immunodeficient persons,
poor efficacy in the case of vaccinemismatch, and a lag time of6
months to prepare a novel vaccine in the case of a pandemic (4).
Hence, antiviral drugs are indispensable as a complementary
strategy to combat influenza virus infections. The recommended
therapy with the neuraminidase inhibitors (NAI) oseltamivir and
zanamivir is subject to concerns about potential drug resistance
(particularly for oseltamivir) (5) and rather modest clinical effec-
tiveness (6, 7). Drug resistance is even more problematic for the
M2 channel blockers amantadine and rimantadine (8).
Given its pivotal role in virus genome replication, the influenza
virus polymerase represents an excellent antiviral drug target (9).
Nucleoside analogue-type viral polymerase inhibitors are a suc-
cessful drug class for diverse virus infections, yet their develop-
ment for influenza has been very slow. One prototypic inhibitor is
T-705 (favipiravir), a nucleobase analogue first reported in 2002
(10) that possesses broad in vitro and in vivo activities against
influenza A, B, and C viruses (10, 11); human and avian (12)
viruses, andNAI-resistant virus strains (11). In addition, thismol-
ecule displays activity against a wide variety of unrelated RNA
viruses (reviewed by Furuta and coworkers [13, 14]). T-705 was
approved in Japan for restricted use against NAI-resistant pan-
demic influenza viruses (15) and is currently in phase 3 trials in
Europe and theUnited States (https://clinicaltrials.gov/ct2/results
?termT-705&SearchSearch). According to available clinical
information, its antiviral effects are similar to those of oseltamivir
(16), giving a statistically significant decrease in symptom dura-
tion (17). An important structural element in T-705 is the carbox-
amidemoiety,which is also present in the broadRNAvirus inhibitor
ribavirin.Theusefulness of ribavirin for influenza therapy seems lim-
ited since clinical trials, performed in the 1980s, indicated that it has
rathermodest efficacy against this virus (18, 19). In anecdotal studies,
ribavirin servedasa last resort to treat (multi)drug-resistant influenza
infections in immunocompromised patients (20, 21). The known
hematological toxicity of ribavirin seems not to occur during short-
term influenza treatment (22).
There are still unknowns regarding the precise anti-influenza
mechanism of T-705 and the potential parallels with ribavirin,
which has been studied more extensively. Inside the host cells,
T-705 and ribavirin undergo conversion to their ribosyl-5=-
mono-, di-, and triphosphate metabolites (23). The high doses
required for T-705 (on the order of 800 to 2,400 mg per day)
could, at least partially, be related to low efficiency of its metabolic
activation (24). Two structural elements are shared by the ribosyl-
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5=-triphosphate forms of T-705 (T-705-RTP) and ribavirin (RBV-
TP). First, the rotating carboxamide moiety (Fig. 1) makes their
base amimic of guanine as well as adenine and provides themwith
ambiguous base-pairing properties. Second, the presence of a nat-
ural ribose implies that in theory, chain elongation is possible in
the case that T-705-RTP or RBV-TP is used as an alternative sub-
strate by the influenza virus polymerase. These two factors could
explain recent observations that cell culture passaging of influenza
virus in the presence of T-705 (25) or ribavirin (26, 27) leads
to virus mutagenesis; this mutagenic effect was also seen in influ-
enza virus-infected mice receiving T-705 therapy (28). Enzymatic
studies showed that influenza virus polymerase recognizes T-705-
RTP as an alternative substrate versus GTP and ATP (29, 30). It
was found that incorporation of a single T-705-RMP into viral
RNA slows down but does not halt viral RNA extension, whereas
two consecutive T-705-RMP incorporation events result in non-
immediate chain termination of viral RNA synthesis (29). The
firstmechanism implies that at lower concentrations, T-705might
be incorporated into nascent or full-length viral RNA, thereby
inducing mutations in the viral genome. In contrast, a direct in-
hibitory effect of RBV-TP on the viral polymerase was seen only at
relatively high compound concentrations (31, 32). Alternatively,
the virus mutagenic effect of ribavirin may be related to a reduced
cellular GTP pool (33) due to the inhibitory action of ribavirin
5=-monophosphate on the cellular IMP dehydrogenase (IMPDH)
enzyme (34).
The diverse mechanisms proposed for T-705 and ribavirin
were largely investigated in separate studies, and the link between
data from enzyme- and cell-based studies still needs to be firmly
proven. To address this, we used all relevant methodologies to
verify the proposedmechanisms,make a side-by-side comparison
between T-705 and ribavirin, and correlate the biochemical and
virological findings. Cell culture studies were performed to inves-
tigate their impact on influenza virus RNA synthesis and infectiv-
ity during one-cycle or multicycle replication, or after serial virus
passaging. The latter allowed us to follow virus mutagenesis dur-
ing prolonged compound exposure. In addition, we assessed the
role of indirect mechanisms (i.e., alterations in the nucleotide
pools) or direct effects on the influenza virus polymerase.
MATERIALS AND METHODS
Virus, cells, and chemical compounds.The influenza virus A/X-31 strain
(a reassortant virus that carries the hemagglutinin [HA] and neuramini-
dase [NA] genes from the A/Aichi/2/68 [A/H3N2 subtype] and all other
genes from A/Puerto Rico/8/1934 [A/H1N1]) was expanded in embryo-
nated hen eggs. Madin-Darby canine kidney (MDCK) cells were kindly
donated by M. Matrosovich (Marburg, Germany), whereas human lung
carcinoma A549 cells were obtained from the American Type Culture
Collection (ATCC). Virus experiments were carried out with infection
medium that consisted of Ultra MDCK medium (Lonza), supplemented
with 0.02% sodium bicarbonate, 2 mM L-glutamine, and 2g/ml of tosyl
phenylalanyl chloromethyl ketone (TPCK)-treated trypsin (Sigma).
T-705 (favipiravir; 6-fluoro-3-hydroxy-2-pyrazinecarboxamide) was
from YouChemicals (Shanghai, China), whereas ribavirin (Virazole) was
from ICNPharmaceuticals. T-705-RTP (35) was synthesized at Alios Bio-
Pharma, Inc., South San Francisco, CA. Ribavirin 5=-triphosphate (RBV-
TP) was purchased from Carbosynth (Berkshire, UK). [8-3H]guanosine-
5=-triphosphate (specific activity: 13.5 Ci/mmol) was acquired from
PerkinElmer (Boston, MA), and [2,8-3H]hypoxanthine (specific radioac-
tivity: 15Ci/mmol)was fromMoravek (Brea, CA). To remove free tritium
label, the [2,8-3H]hypoxanthine was purified by reverse-phase high-per-
formance liquid chromatography (HPLC) analysis with an ammonium
formate buffer, followed by evaporation under vacuum.
Multicycle assays. To perform the cytopathic effect (CPE) reduction
assay (36),MDCKcells were seeded in 96-well plates at 7,500 cells perwell.
Sixteen hours later, the compounds were added, followed by the virus
(multiplicity of infection [MOI]: 0.0004 PFU per cell). After 3 days of
incubation at 35°C, virus-induced CPE and compound cytotoxicity were
monitored by microscopy and then confirmed by the formazan-based
MTS cell viability assay (Cell Titer 96 Aqueous One Solution cell prolifer-
ation assay from Promega). The antiviral 50% effective concentration
(EC50) was defined as the concentration producing 50% inhibition of
virus-induced CPE.
To determine the effect on virus yield, cells were infected as described
above (MOI: 0.0004 PFUper cell) but at 1 h postinfection (p.i.), the superna-
tantwas replaced bymediumcontaining compound to remove the unbound
virus. After 72 h of incubation, supernatants were collected. The infectious
virus titer was determined by adding serial dilutions of these supernatants to
freshMDCK cells (four wells per dilution) and assessing the viral CPE at day
3 p.i. The titer, expressed as 50% cell culture infective dose (CCID50), was
calculated by themethod of Reed andMuench (37). In parallel, the superna-
tants were submitted to one-step reverse transcription-quantitative PCR
(RT-qPCR) to determine the viral RNA (vRNA) copy number, using the
CellsDirect One-Step qRT-PCR kit from Invitrogen. All details on sample
preparation, PCR program, M-gene-directed primers, probe, and plasmid
standard can be found elsewhere (38).
To perform the plaque assay, MDCK cells were seeded into 12-well
plates at 125,000 cells per well in Opti-MEM I medium (Life Technolo-
gies). On the next day, the virus (MOI: 20 to 50 PFU per well) was added
to the cells and allowed to adsorb for 1 h at 35°C. After removal of un-
bound virus, the compounds were added together with overlay medium
to obtain a final concentration of 0.4% ultrapure agarose in Opti-MEM I.
Three days later, the cell monolayers were fixated in 1.2% formaldehyde
and then stained with 0.1% crystal violet.
One-cycle time-of-addition experiments.MDCKcellswere seeded in
24-well plates at 125,000 cells per well. After 16 h, X-31 influenza viruswas
added at an MOI of 0.0004 PFU per cell, and the compounds were added
at12, 0, 1, 2, 3, 4, 5, 6, 7, or 8 h p.i. At 10 h p.i., total cellular RNA extracts
were prepared and the vRNA copy number was determined by two-step
RT-qPCR (39). To quantify the vRNA in the inoculum, an RNA extract
was prepared at time zero from virus-infected cells receiving no com-
pound. To determine the kinetics of vRNA synthesis, virus-infected cells
were lysed at 0 to 10 h p.i., and two-step RT-qPCR analysis was performed
as described above.
Virus passage experiments and full virus genome sequencing.Three
passage experiments (at an MOI of 0.0004 to 0.004 PFU per cell) were
performed which were separated by time. MDCK cells, seeded in 96-well
plates, were infected with influenza virus and exposed to T-705, ribavirin,
or medium. After 3 days of incubation, conditions showing obvious CPE
were selected, and from these wells, the cells plus supernatants were har-
vested and frozen at80°C. These yields were serially diluted and inocu-
lated onto fresh MDCK cells, with new addition of T-705, ribavirin, or
FIG 1 Chemical structures of T-705 and ribavirin.
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medium. The procedure was repeated for a total of 14 passages in exper-
iment 1, 12 passages in experiment 2, and 14 passages in experiment 3.
For full virus genome sequencing on the 12th/14th or intermediate
virus passages, the samples (cells plus supernatant) were processed, PCR
amplified, and analyzed on an Illumina HiSeq2000 platform, followed by
analysis of the deep-sequencing data (for details, see the supplemental
material). Briefly, to assess the mutational load in the deep-sequenced
virus samples, we first reconstructed the evolution of divergence in the
presence or absence of T-705 or ribavirin, with a focus on the coding
genome regions, by comparing the majority-rule consensus sequences
obtained with CLC Bio software v. 7.5.1 (Qiagen). Next, we explored the
overall genetic diversity by contrasting a site-specific measure of nucleo-
tide diversity (the standard Shannon entropy) (40) for the populations
obtained under T-705 or ribavirin or the controls that were passaged
without compound. Finally, we compiled the nonsynonymous changes
with respect to the parent virus stock in the consensus sequences of the
viruses obtained from the last passages and, in case of experiment 3, the
intermediate passages.
HPLC analysis of cellularNTPpools.To quantify theNTP (i.e., ATP,
CTP, GTP, andUTP) pools,MDCK cells in 25-cm2 flasks were exposed to
T-705 or ribavirin for 1 to 72 h (specified in Results). To prepare extracts,
the cells were washed three times with blank medium and then subjected
to trypsinization, cell counting, and centrifugation. The cell pellet was
resuspended in 500 l of ice-cold methanol-water (2:1), and after stand-
ing for 10 min on ice, the extracts were clarified by centrifugation at
16,000 g. HPLC analysis was performed on a Partisphere SAX strong-
anion exchange column using the equipment and phosphate buffer gra-
dient described previously (41). The retention times of ATP, CTP, GTP,
and UTP were 20, 22, 23, and 27 min, respectively, and UV detection was
done at 259 nm. To normalize the data, the absolute peak areas were
converted into the peak area per cell.
Enzymatic assay with influenza virus polymerase. Viral ribonucleo-
proteins (vRNPs) were isolated from virions and purified by gradient
ultracentrifugation (42–45). These vRNPs contain the native PA-PB1-
PB2 polymerase enzyme and, as the template for transcription, viral RNA
complexed to nucleoprotein. To determine their inhibitory effects on vi-
ral RNA elongation in competitionwithGTP, the compoundswere added
to a reaction mixture (final volume: 25 l) containing 50 mM Tris (pH
8.0), 100mMKCl, 1mMdithiothreitol, 5 mMMgCl2, 0.4 U/l of recom-
binant RNasin (Promega), 200 M ApG primer [adenyl (3=-5=)guanos-
ine, obtained from Sigma], 100MUTP, 100MCTP, 500MATP, 2.2
M GTP, and 1.5 M [8-3H]GTP. After addition of the isolated vRNPs,
the samples were incubated for 1 h at 30°C. The amount of radioactivity
incorporated into viral RNA was quantified by a filter-based method as
described elsewhere (42, 43).
Cell-based method to measure inhibition of IMPDH. To estimate
the compounds’ effects on the conversion of hypoxanthine to GMP
(which requires catalysis by hypoxanthine guanine phosphoribosyltrans-
ferase (HGPRT) and IMPDH, consecutively), a tritium release assay was
performed,whichwas a variation of an establishedmethod for suspension
cells (46). A549 cells seeded into 24-well plates were preincubatedwith the
compounds for 4 h at 37°C. Then [2,8-3H]hypoxanthine was added at 0.7
Ci per well and a total concentration of 4.4 M. After 45 min of incu-
bation, the supernatants were mixed 1:1 with an ice-cold suspension con-
taining 150mg perml of activated charcoal and 7.5% trichloroacetic acid.
After standing for 10 min on ice, followed by high-speed centrifugation,
the clarified supernatants were collected for scintillation counting.
Statistical analysis. To analyze differences between two conditions,
the unpaired two-sided Student t test was used, setting a P value of0.05
as the cutoff for statistical significance.
RESULTS
At high concentrations, T-705 and ribavirin shut off virus rep-
lication; at lower concentrations, T-705 gives abundant produc-
tion of noninfectious virus particles.There is some divergence in
the literature regarding the antiviral activity of T-705 in influenza
virus-infected MDCK cells. Furuta et al. (10) reported EC50s,
based on a plaque reduction assay, in the range of 0.08 to 3 M,
whereas in the CPE reduction assay conducted by Baranovich et
al. (25), T-705 had EC50s in the range of 11 to 17M.This concurs
with the EC50 of 11 M that we found in this study (Table 1) and
a previous study (24). Importantly, in each of these investigations,
T-705 was devoid of cytotoxicity at the highest concentration
tested, i.e., 600 M (Table 1), 1,000 M (25), or 6,400 M (10).
The selectivity index of T-705 by far exceeds that of ribavirin
which, in our CPE assay, displayed an EC50 for influenza virus of
8.1 M yet visible cytostatic activity at 100 M.
In parallel, we determined the virus yield in the supernatant
after multiple replication rounds (i.e., at 72 h p.i.), using an infec-
tious virus titration (CCID50) assay as well as RT-qPCR quantifi-
cation of vRNA to estimate the number of virus particles. Both
T-705 and ribavirin produced a dose-dependent reduction in in-
fectious virus yield (Fig. 2a). This dose-dependent effect was also
seen by RT-qPCR (Fig. 2b) with EC99s (corresponding to 100-fold
reduction in vRNA copy number) of 13M for T-705 and 14M
for ribavirin (Table 1). Strikingly, when the data were expressed as
the ratio of CCID50 to vRNA copy number (Fig. 2c), the T-705-
exposed cells were found to produce high quantities of vRNA that
was not associated with infectious virus. Compared to the condi-
tion receiving no compound, the CCID50-to-vRNA ratio was 49-
fold lower for virus exposed to 20 MT-705. This effect was seen
only at low T-705 concentrations (i.e., 20, 8, or 3.2 M), since at
50 M T-705, no virus was detected by either CCID50 or RT-
qPCR assay (Fig. 2a and b). Complete inhibition was also seen
with ribavirin at concentrations of50M, but lower concentra-
tions of ribavirin did not give the reduction in virus infectivity that
was seen with T-705.
Next, the virus-containing supernatants collected as described
above were used to infect MDCK cells in the presence or absence
of T-705 or ribavirin, and again, the virus yield at 72 h p.i. was
determined by CCID50 and RT-qPCR analysis. In this passage,
passage 2 (Fig. 2d), T-705 again produced a marked (up to 400-
fold) decrease in the CCID50-to-vRNA ratio. When the T-705-
exposed passage 1 virus was incubated without compound (see
hatched bars in Fig. 2d), the CCID50-to-vRNA ratio at least par-
tially returned to the level seen in the no-compound control.
The pronounced effect of T-705 was not seen with ribavirin. In
passage 1, ribavirin at a concentration of 20, 8, or 3.2 M gave
TABLE 1 Antiviral activities of T-705 and ribavirin in influenza virus-
infected MDCK cellsa
Compound
Antiviral activity
MCCd
(M)
CPE assay result,
EC50
b (M)
RT-qPCR assay resultc
EC90 (M) EC99 (M)
T-705 11 0 9.2 1.1 13 1 600
Ribavirin 8.1 1.3 9.1 1.9 14 2 100 0
a Data are means SEMs from 3 independent experiments.
b EC50, compound concentration giving 50% inhibition of virus-induced CPE, as
determined by microscopy at 72 h postinfection.
c EC90 and EC99, compound concentrations producing 1-log10 and 2-log10 reductions
in virus yield, respectively, as determined by RT-qPCR analysis of vRNA copy number
in the supernatant at 72 h postinfection.
d MCC, minimum cytotoxic concentration, i.e., concentration giving minimal
alterations in cell morphology, as determined by microscopy.
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CCID50-to-vRNA ratios similar to those of the no-compound
control (Fig. 2c), and in passage 2, the reduction in particle infec-
tivity was at maximum 28-fold (Fig. 2d).
In combination, these data indicate that T-705 interferes with
influenza virus replication in a dual manner. The compound dose
dependently inhibits viral replication and RNA synthesis, with
complete shutoff at concentrations of 50 M. At lower T-705
concentrations, the inhibition is only partial and nonviable viral
genomes are abundantly produced. In the case of ribavirin, the
formation of noninfectious particles is much less pronounced.
Both T-705 and ribavirin inhibit first-cycle viral RNA syn-
thesis; forT-705, activation is slowat low compound concentra-
tions. A time-of-addition experiment was performed, in which
the compoundswere added at different timepoints, andfirst-cycle
vRNA synthesis (of the M gene) was monitored at 10 h p.i. First,
we analyzed the kinetics of vRNA synthesis during this one cycle
by performing RNA extractions at 1-h intervals and quantifying
the vRNA levels in the cells. As shown in Fig. 3a, vRNA synthesis
started at 5 h and then showed an exponential phase between 6
and 8 h, after which it slowed down.
When ribavirin (at 20M) or T-705 (at 250M)was added at
the time of virus infection (i.e., time zero) or at 1, 2, or 3 h p.i.,
both compounds produced 100% inhibition of vRNA synthesis
(i.e., increase in vRNAcompared to virus input 1 [Fig. 3b]). The
inhibition was clearly lower when the compounds were added at 4
h p.i. or later. The curve of ribavirin fully overlapped that of T-705
at 250 M; in both cases, the compound’s activity was mainly
situated between 3 and 5 h p.i. When T-705 was applied at the
lower concentration of 100 M, the time-of-addition curve
shifted to the left (Fig. 3b). A plausible explanation is that the
formation of T-705-RTP is slower at lower concentrations of
T-705, as demonstrated by Smee et al. (47). Hence, an experiment
was performed inwhich different concentrations of T-705 or riba-
virin were added at either12 or 0 h p.i. Compound preincuba-
tion gave a clear advantage for T-705 at 20 or 50 M but had no
impact for the 100 and 250 M conditions (compare dark and
light gray bars in Fig. 3c). This means that once activated, T-705
provided at least a 400-fold (2.6-log10) reduction in first-cycle
vRNA synthesis at concentrations of 50 M or more; at 20 M,
the reduction was 27-fold (1.4 log10). This dose-dependent inhi-
bition of vRNA synthesis was also seen with ribavirin, but in this
case, the effect was the same whether or not compound preincu-
bation was applied.
T-705 and, to a lesser degree, ribavirin induce mutations in
the influenza virus genome upon sustained drug exposure. To
investigate how influenza virus populations evolve when exposed
to T-705 or ribavirin for longer periods, we performed three in-
dependent virus passage experiments. In each passage, virus was
grown for 72 h in the absence or presence of compound, after
which the virus was harvested and used to infect fresh cells. This
virus subcultivation was limited to 12 or 14 passages. In the first
two experiments, we applied T-705 at different concentrations
(3.2, 8, or 20 M) and selected the highest concentration condi-
tion showing viral CPE to perform each next passage (see Table S1
in the supplemental material). This approach ensured that each
passage was done at the maximum mutagenic pressure tolerated
FIG 2 Production of noninfectious virus particles at low concentrations of T-705. MDCK cells were exposed to influenza virus and T-705 or ribavirin, and the
virus present in the supernatants at 72 h p.i. was quantified. (a) Infectious virus titer, expressed as CCID50; (b) vRNA copy number, determined by RT-qPCR; (c)
ratio of CCID50 to vRNA copy number. (d) The passage 1 supernatants were used to infect fresh MDCK cells with, again, addition of T-705, ribavirin, or
compound-free medium. After 72 h, the passage 2 supernatants were submitted to virus titration and RT-qPCR analysis. The graph shows the ratio of CCID50
value to vRNA copy number in function of compound concentration during passage 2; the hatched bars mark the conditions in which no compoundwas added.
	DL, below the detection limit. Data are the means  SEM (n  4). **, P 	 0.005; *, P  0.05 (versus the no-compound [cpd] condition; Student t test on
log-transformed values).
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by the virus and also increased the chance of selecting a mutant
virus with altered fidelity. However, at 20 MT-705, the infectiv-
ity tended to be so low that the subsequent passage required a
reduction in compound concentration in order to recover the
virus. Therefore, passage experiment 3 was conducted with a con-
stant concentration of 8 M T-705 or ribavirin, throughout pas-
sages 1 to 14.
After performing deep-sequencing on the 12th or 14th virus
passage, we first analyzed the point mutations in their majority-
rule consensus sequences. Clearly, the virus accumulated muta-
tionswhen exposed toT-705 and this phenomenonwas reproduc-
ible among the three passage experiments. In total, 37, 48, and 45
mutations were detected under T-705 (Table 2), compared to 2, 4,
and 11 mutations under the no-compound condition, meaning
that in the presence of T-705 the dominant nucleotide was re-
placed at 18, 12, and 4 times more positions in experiments 1, 2,
and 3, respectively. In the case of ribavirin, the effect was more
variable, with 11-fold and 1.6-fold increases in consensus nucleo-
tide changes in experiments 2 and 3, respectively. For both com-
pounds, G¡A or C¡U transitions represented the majority (i.e.,
62 to 89%) of the total number of mutations. This is in line with
the view that T-705 and ribavirin are ambiguous purine pseudo-
bases that mimic both guanine and adenine.
By sequencing the intermediate passages in experiment 3, the
mutation rate was shown to be comparatively higher under the
T-705 condition (Fig. 4). This trend was stable throughout the 14
passages, indicating that the virus population incorporatedmuta-
tions at a rather constant rate.
The mutations were distributed over all eight viral genome
segments, with a trend toward somewhat higher mutation fre-
quency in theNS gene (see Table S2 in the supplementalmaterial).
Nonsynonymous changes accounted for 43%, 54%, and 35% of
the mutations detected in the conditions under T-705, ribavirin,
and no compound, respectively. The amino acid substitutions
were present in all viral proteins (including the PA, PB1, and PB2
subunits of the polymerase complex), but none was present in all
three experiments. Hence, no particular substitution seemed to be
associated with compound (T-705 or ribavirin) selection pressure
or cell culture adaptation. Themajority of themutations (whether
silent or not) remained during subsequent passaging; also, the two
T-705 conditions that underwent passage 14 with or without
T-705 had identical consensus nucleotide sequences (see last data
point in Fig. 4). Since our data may help to assess the viability of
certain amino acid changes, a complete list of all substitutions
present at frequencies of50% is given in Table S3 in the supple-
mental material.
We also examined the overall diversity of the virus populations
by contrasting the per-site standard Shannon entropy distribu-
tions for the compound-exposed conditions with those of the par-
ent stock (used at the start of the experiments) and the condition
of passage without compound (Fig. 5). Positions in the genome
for which all variants in the population share the same nucleotide
have a Shannon entropy of zero. This measure of uncertainty in-
corporates both the frequency information and the number of
possible characters and has a maximum value when all possible
characters are present at equal frequencies. Figure 5a shows that
the per-site diversity distributions were generally shifted upwards
in passages 12 and 14 under T-705 or ribavirin compared to those
of the unexposed populations. This increase in entropy was par-
ticularly pronounced (P 	 0.005) in experiment 3, in which the
concentration of T-705 or ribavirin was kept constant at 8M. By
analyzing the intermediate passages, we found that the increase in
population diversity was already significant within two passages
under T-705 or ribavirin. With T-705, the entropy seemed to
reach amaximumplateau after 10 passages (Fig. 5b); the high level
of population diversity induced by T-705 was not seen within 14
passages under ribavirin. The effect of T-705was readily reversible
FIG 3 Inhibitory effect on influenza virus vRNA synthesis within one repli-
cation cycle. (a) Time course for intracellular vRNA synthesis. MDCK cells
were infected at time zero, and at several time points the vRNA level (for the
M-gene) was determined by RT-qPCR. (b) Intracellular vRNA levels at 10 h
p.i. after exposure to T-705 (at 100 or 250 M) or ribavirin (at 20 M), as a
function of compound addition time. (c) Effects of the compounds when
added at different concentrations, at either 12 h or 0 h before virus infection.
The data in panels a to c are expressed as the fold increase in vRNA copy
number relative to the virus input added at time zero. Data aremeans SEMs
(n 3).
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since the entropy value practically normalized when T-705 was
omitted for one single passage (Fig. 5c).
Notably, there was no increase in the number of variable sites
in the presence of T-705 or ribavirin, compared to the controls
without compound. For T-705, between 88%and 94%of the vari-
able sites (i.e., showing nonzero entropy) were shared, and for
ribavirin this fraction was between 86% and 94%. These results
suggest that the increased entropy in the virus populations under
T-705 or ribavirin results from a higher proportion of variants
harboring alternative nucleotides at the variable positions due to a
mutagenic effect.
Viruses passaged under T-705 or ribavirin had reduced rep-
lication fitness and particle infectivity but unaltered antiviral
susceptibility. To characterize the phenotype of the viruses ob-
tained after 14 passages, a plaque assay was performed (Fig. 6a).
Each virus was fully inhibited by 20Mribavirin or 50MT-705,
whereas 20 M T-705 gave a clear reduction in plaque size and
number. Compared to the virus grown in the absence of com-
pound, the viruses passaged under T-705 or ribavirin displayed a
smaller plaque size (Fig. 6a, left images), indicating reduced rep-
lication fitness. The sensitivity to T-705 or ribavirin was not re-
duced after 14 passages, as evident from the antiviral EC50s deter-
mined by CPE assay (Fig. 6b) and confirmed by a colorimetric
formazan-based cell viability assay (data not shown). Finally, a
virus yield study was done using the CCID50 and RT-qPCR assays
(see above). The passage 14 viruses harvested under T-705 or riba-
virin had impaired particle infectivity compared to the virus
grown without compound, the reductions in CCID50-to-vRNA
ratio being800-fold for T-705 and50-fold for ribavirin (Fig.
6c). For T-705, the CCID50-to-vRNA ratios were similar in the
viruses harvested after 1 (Fig. 2c), 2, or 6 passages and then
dropped at passages 13 and 14 (Fig. 6c). Thismeans that the prop-
erty of the virus to produce noninfectious particles when exposed
to T-705 gradually increased during these 14 passages. The parti-
cle infectivity practically returned to the normal level when T-705
was omitted during one (i.e., the 14th) passage (see hatched bar in
Fig. 6c, 14). In contrast, the condition grown in the absence of
compound showed unaltered CCID50-to-vRNA ratios from pas-
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FIG 4 Mutation rate during serial virus passaging in the presence of T-705 or
ribavirin. In passage experiment 3, deep-sequencing analysis was performed at
passages 2, 6, 10, 13, and 14 (concentration of T-705 or ribavirin: 8 M from
passage 1 until passage 14). The y axis shows the total number of point muta-
tions in the full viral genome. For the T-705 curve, the solid black circles
denote the condition receiving T-705, whereas the open circle marks the con-
dition in which T-705 was omitted during passage 14.
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sages 2 to 14. For ribavirin, the particle infectivity was 10- to 50-
fold lower, with no downward trend during serial virus passaging.
RibavirinbutnotT-705 causes fast andprofoundGTPdeple-
tion and NTP imbalance. To define the biochemical basis for
the mutagenic effect of T-705 and ribavirin upon influenza
virus, we first measured their effects on the cellular NTP pools
in MDCK cells. As shown in Fig. 7a, ribavirin caused manifest
GTP depletion after 24 h, the reductions in the GTP pool being
81%, 56%, and 37% at 100, 30, and 10 M ribavirin, respec-
tively (P  0.06 for comparison of the GTP peak area in un-
treated cells versus the 30 or 100 M ribavirin condition). This
effect coincided with a slight increase in the ATP pool and
pronounced increase in the pools of CTP and, in particular,
UTP (i.e., P	 0.05 for comparison of the UTP peak area in the
untreated versus 30 or 100 M ribavirin condition). It was also
accompanied by a cytostatic effect (i.e., 34% reduction in the
cell number under the condition of 100 M ribavirin). In the
case of T-705, the GTP pool was reduced by 67% at 600Mand
42% at 60 M (Fig. 7a) (P  0.2 for comparison of the GTP
peak area in untreated cells versus any of the two T-705 condi-
tions). No alterations were seen in the pools of ATP, CTP, or
UTP, nor was there any cytostatic effect at 600 M T-705.
We next determined the kinetics of this GTP depletion (Fig.
7b). To our surprise, the effect of 30 M ribavirin was already
visible at 1 h and achieved itsmaximum at 2 h (i.e., 91% reduction
in the GTP pool; P 	 0.005 for comparison with the untreated
FIG 5 Population sequence diversity of the viruses passaged under T-705 or ribavirin. (a) Shannon entropy analysis was performed on the deep-sequencing data
frompassage experiments 1 (12 virus passages), 2 (14 passages), and 3 (14 passages) (see Table S1 in the supplementalmaterial for all details). (b) Entropy analysis
for the intermediate virus passages collected in experiment 3. (c) In experiment 3, the 14th passage was done either in the presence of 8MT-705 (on the right)
or in the absence of compound (in themiddle). In panels a to c, the data on the left represent the parent virus that was used at the start of the passage experiment.
**, P 	 0.005; *, P  0.05; NS, not significant, i.e., P  0.05 (two-sided Student t test) for comparison between the T-705 or ribavirin versus no-compound
condition (a and b) and between passage 14 in the presence versus absence of T-705 (c).
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condition). After 8 h, the GTP pool was gradually restored, and at
72 h, it was 78% that of untreated cells. These data indicate that (i)
the conversion of ribavirin to its 5=-monophosphate is very fast in
dividing MDCK cells, (ii) the GTP pool in these cells is very dy-
namic, and (iii) upon GTP depletion by ribavirin, a feedback
mechanism is initiated to restore the GTP pool; a possible expla-
nation is upregulation of the HGPRT purine salvage enzyme.
With T-705 (concentration: 200 M), the picture was entirely
different. At 4 h, the GTP level was still normal; then it gradually
declined to reach a plateau at 24 to 72 h, when the GTP pool was
40% of the control level. The GTP depletion by T-705 was not
restored within the 72-h observation period.
Hence, the GTP depleting effects of ribavirin and T-705 clearly
differ with regard to magnitude and kinetics, and only ribavirin
causes an NTP imbalance. Although the GTP depletion by ribavi-
rin has been documented in other studies (34, 48), we are the first
to recognize the fast kinetics of this effect.
Ribavirin acts via the cellular IMPDH enzyme, whereas
T-705 acts upon the influenza virus polymerase. We next per-
formed a cell-based IMPDH inhibition assay using [2,8-3H]hy-
poxanthine. Upon addition to cells, this purine base is converted
byHGPRT to IMP,which is subsequently converted by IMPDHto
GMP. The second reaction results in release of the tritium label at
position 2 of the purine base, which can be detected in the super-
FIG 6 Fitness and antiviral sensitivity after 14 serial passages under T-705 or ribavirin. (a) Plaque assay with viruses obtained after 14 passages in the presence
of 8 M T-705 (first row), 8 M ribavirin (second row), or no compound (third row) along with an uninfected control (fourth row). The plaque assay was
performed in, from left to right, the absence of compound or the presence of 20 or 50 MT-705 or 20 M ribavirin (RBV). Note that the slight disturbance of
the cell monolayer in the ribavirin-treated wells is due to its cytostatic effect and not to virus plaque formation. (b) Antiviral sensitivity of these passage 14 viruses
to T-705, ribavirin, and zanamivir, expressed as the EC50 by CPE assay (means SEMs; n 3). (c) Noninfectious particle production in the viruses harvested
after 2, 6, 10, 13, or 14 passages under 8MT-705 or ribavirin. The viruses were subjected to infectious virus titration by CCID50 assay and vRNA quantification
by RT-qPCR. The y axis shows the CCID50 (top graph), vRNA copy number (middle graph), or the ratio (bottom graph). The hatched bar represents the T-705
condition in which the last (14th) passage was done in the absence of compound. Data are means SEMs (n 3) from three analyses.
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natant. The clinically used IMPDH inhibitor mycophenolic acid
was included as a control. A dose-dependent inhibition of the
IMPDH reaction was seen with ribavirin and mycophenolic acid,
their EC50s being 7.6 and 0.55M, respectively (see Fig. S1a in the
supplementalmaterial).No effectwas seenwithT-705 at up to 200
M, the highest concentration tested. When all mechanistic data
for ribavirin are combined, a striking correlation can be seen be-
tween the concentrations producing GTP depletion and IMPDH
inhibition on the one hand and virus inhibition on the other hand.
Finally, to investigate whether the ribosyl-5=-triphosphate
forms of T-705 and ribavirin have a direct effect on the viral poly-
merase, we conducted enzymatic studies with isolated influenza
virus vRNPs. The 50% inhibitory concentrations (IC50s; for inhi-
bition of [8-3H]GTP incorporation) were 27 M for the obligate
chain terminator 3=-dGTP and 4.6 M for the nonobligate chain
terminator 2=-fluoro-2=-dGTP (49) (see Fig. S1b in the supple-
mental material). An even stronger inhibition was seen with
T-705-RTP, with an IC50 of 2.7 M; this value is similar to that
reported elsewhere (29). In contrast, RBV-TP manifested only
weak inhibition of influenza virus polymerase-dependent RNA
synthesis, since its IC50was as high as 216M,which is in linewith
the values reported by others (31, 32).
DISCUSSION
T-705 is the first influenza virus polymerase inhibitor achieving
market approval (in Japan) or advanced clinical testing (in Europe
and the United States). It has an excellent therapeutic index that is
far superior to that of ribavirin, another purine pseudobase deriv-
ative. The enzymatic studies by Furuta and colleagues (23, 30)
identified T-705-ribosyl-5=-triphosphate as a strong inhibitor of
the influenza virus polymerase. For ribavirin, the cellular IMPDH
enzyme was presented as the indirect and predominant target for
antiviral activity (34, 50), although inhibition of the influenza vi-
rus polymerase was also reported (23, 31–33). Since both T-705
(25, 28) and ribavirin (26, 27) were recently reported as influenza
virus mutagens, the aim of our study was to make a side-by-side
comparison between these two molecules, using cell-based virus
infection methods combined with biochemical assays to verify
and, particularly, link all possible mechanisms of action. A sche-
matic summary of our findings is presented in Fig. 8.
First-cycle viral vRNA synthesis is fully inhibited at T-705 con-
centrations of50 M and ribavirin concentrations of20 M,
provided that they are added no later than 2 h prior to the onset of
vRNA synthesis. For ribavirin, this is explained by the fact that its
GTP-depleting effect reached its maximum after 2 h. For T-705,
the requirement of early addition is related to the slow and con-
centration-dependent rate of its metabolic activation as shown by
Smee et al. (47). Inhibition of viral RNA synthesis was also seen in
themulticycle (72-h) assay, since both agents gave complete shut-
off at 50M. At lower (8 or 20M) concentrations, a remarkable
divergence was seen, since T-705 but not ribavirin gave rise to
FIG 7 NTP pools in MDCK cells exposed to T-705 or ribavirin. (a) The compounds were added to uninfected MDCK cells, and 24 h later, cell extracts were
prepared and analyzed by HPLC. The bars represent the GTP, ATP, UTP, and CTP pools (expressed as peak area per cell; left y axis) and the diamonds indicate
the cell number (right y axis), both expressed as the percentage versus the no-compound condition. (b) The experiment was performed as described for panel a
yet at one single concentration of T-705 (200 M) or ribavirin (30 M) and applying different compound incubation times (x axis). The y axis shows the GTP
pool relative to that under the no-compound condition. Data are means SEMs (n 3 to 10).
Effects of T-705 and Ribavirin on Inﬂuenza Virus
November 2016 Volume 60 Number 11 aac.asm.org 6687Antimicrobial Agents and Chemotherapy
 o
n
 O
ctober 23, 2016 by KU Leuven University Library
http://aac.asm
.org/
D
ow
nloaded from
 
abundant production of noninfectious virus particles.When virus
was passaged under T-705, the infectivity gradually declined to
reach a minimum after 13 passages, when particle infectivity was
800-fold beyond that of control virus. With ribavirin, the reduc-
tion in particle infectivity was much less pronounced and did not
evolve over 14 passages.
Deep-sequencing analysis of the passaged viruses demon-
strated that both agents induced gradual accumulation of point
mutations in the viral genome, of which 62 to 89% were G-to-A
plus C-to-U transitions. The number of point mutations after 12
to 14 passages was increased 12-fold by T-705 and 6-fold by riba-
virin, meaning that themutagenic effect of T-705 was 2-foldmore
pronounced. The fact that we performed three independent pas-
sage experiments with whole-virus genome sequencing adds to
the relevance of these estimated mutation frequencies. We ob-
served interexperimental variations in the mutational burden for
individual genome segments, meaning that a mutational analysis
that is restricted to some specific segment(s) may give a biased
result. Our deep-sequencing approach also enabled entropy anal-
ysis for sequence diversity, which confirmed that T-705 has a
higher mutagenic effect upon influenza virus than ribavirin. In
our study, the population sequence diversity increased within two
passages under T-705 to reach a maximum after 10 to 14 passages
and quickly declined when T-705 was no longer added.
Our investigation is the first in which the mutagenic effects of
T-705 and ribavirin on influenza virus have been directly com-
pared. In line with our data (49-fold-lower virus infectivity at 20
MT-705), Baranovich et al. (25) found that T-705 reduces virus
infectivity 18-fold at 10 M and 740-fold at 100 M. In their
passage experiment with a low viral MOI similar to the one we
used, the steepest decrease in viral infectivity was seen at10M
T-705, which is in the same concentration range as ours. T-705
(applied at gradually rising concentrations) increased the number
ofmutations by a factor of3 after 24 passages (25). Cheung et al.
(26) noted, after four passages under 35M ribavirin, an increase
in the number of mutations by a factor of 4. Pauly and Lauring
(27) observed a 1.7-fold increase in mutation number after one
virus passage with 5 or 40 M ribavirin. Experimental variations
make it difficult to compare these separate reports, indicating the
importance of side-by-side analyses like the one that we did. Be-
sides variations in compound concentrations, the viral MOI
seems particularly relevant, since Baranovich et al. (25) found that
virus extinction by T-705 (due to reducing infectivity) occurs
within 24 passages when a low viral MOI is used and 3 passages in
the case of a high MOI, a condition that promotes formation of
noninfectious particles (51). Also, laboratory strains (such as the
X-31 strain that we used) have high intrinsic replication rates, and
their stocks can contain high quantities of noninfectious particles
after passaging in cell culture or eggs. These factors could render
themmore sensitive to lethalmutagens than low-passage-number
clinical isolates.
The viruses that we obtained under T-705 or ribavirin con-
tainedmany nonsynonymousmutations distributed over all eight
genome segments. In contrast, Baranovich et al. (25) detected, in
their viruses grown under T-705, only a few substitutions in the
NA or HA protein. These authors concluded that the reduced
fitness and subsequent virus extinction are explained by lethal
mutagenesis. According to this concept, a mutagenic antiviral
agent increases the mutation rate of the virus population above a
threshold level, rendering the virus nonviable (52). Our results
confirm that at low concentrations, T-705 and, to a lower degree,
ribavirin induce a mutated and genetically diverse influenza virus
population.However, in our experiments, the reduced replication
fitness of these virus populations seems to be explained by accu-
mulation of fitness-reducing amino acid substitutions. This vari-
ety of amino acid changes spread over different viral proteins was
also seen in the ribavirin passaging experiments by Pauly and Lau-
ring (27) and Cheung et al. (26). In the latter investigation, sub-
FIG 8 Summary scheme. In the left column, the different mechanisms explored in our experiments are listed. T-705 and ribavirin have similar EC50s, and both
shut off viral RNA synthesis at concentrations of50M. T-705-RTP is an efficient alternative substrate inhibitor for the influenza virus polymerase; combined
with its ambiguous base properties, this explains the strong virus mutagenic effect of T-705 at concentrations of 20 M. T-705 does not affect the cellular
IMPDH enzyme and has no cytostatic effect. Ribavirin acts via IMPDH inhibition; the resulting GTP depletion and NTP imbalance explain its virus mutagenic
and clear cytostatic effects.
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stitution V43I in PB1 was identified, after 17 passages, as confer-
ring weak (2-fold) resistance to ribavirin, and this effect was
attributed to slightly higher fidelity of the mutant polymerase. In
our study, no resistance to T-705 or ribavirin emerged within 14
passages. We did not detect the PB1-V43I change despite deep-
sequencing analysis. Likewise, the fact that the mutation rate re-
mained stable during 14 passages under T-705 indicates that a
mutant virus with increased fidelity was not selected under our
experimental conditions. In another study, T-705 resistance did
not develop within asmany as 30 virus passages (14), and no signs
of T-705 resistance were seen in a recently described patient study
(17).
Regarding the biochemical mechanism, a clear distinction can
be seen between T-705 and ribavirin. For ribavirin, the inhibitory
effect upon viral RNA synthesis nicely correlates with its GTP-
depleting effect, in both time and concentration dependency.
Somewhat to our surprise, we observed that this GTP depletion,
which is explained by inhibition of the IMPDH enzyme, is very
fast and profound (90% reductionwithin 2 h) and is accompanied
by amarked increase in the pools of UTP and CTP. Another study
has shown that GTP depletion following IMPDH inhibition (in
this case, by mycophenolic acid) coincides with an increase in the
UTP pool (53). Thus, the virus mutagenic effect during sustained
exposure to ribavirin seems to be explained by a skewedUTP/GTP
balance. Ribavirin-5=-triphosphate is only marginally active in in-
fluenza virus polymerase enzyme assays, with IC50s of 70M(32),
100 M (31), and 216 M (our study). Hence, we consider it
improbable that ribavirin could function as an alternative sub-
strate for the polymerase and cause mutations in the influenza
virus genome after its incorporation.
For T-705, the picture is entirely different, since it did not
inhibit the IMPDH reaction in our cell-based assay or in the en-
zymatic study by Furuta et al. (23). We saw some drop in the GTP
pool at high T-705 concentrations (i.e., 67% reduction at 600M,
a concentration that is 60-fold higher than its antiviral EC50), but
the levels of UTP or CTP were unchanged. Minor GTP depletion
was also reported by Smee et al. (47), who saw a 36% reduction in
the GTP pool in cells receiving 1,000 MT-705. Possibly, T-705-
ribosyl-5=-monophosphate requires conversion by GMP kinase,
which at higher T-705 concentrations could interfere with the
biosynthesis of GTP. It seems implausible that GTP depletion
would be a factor in the anti-influenza virus effect of T-705.
Rather, the strong inhibitory effect of T-705-RTP at the viral poly-
merase level implies that it functions as an alternative substrate for
this enzyme. Consistent with the enzymatic experiments of Jin et
al. (29), our cell culture data demonstrate that T-705 shuts off viral
RNA synthesis at high concentrations. At lower concentrations, it
is incorporated into the viral genome, giving either chain termi-
nation or chain elongation and inducing primarily G-to-A and
C-to-U transitions due to its ambiguous base-pairing behavior.
Incorporation of T-705 into the viral genomemight be a relatively
frequent event: the viral polymerase was shown to incorporate
T-705-ribosyl-5=-triphosphate with an efficiency that is only 19-
and 30-fold lower than those of GTP and ATP (29), respectively.
This explains why the virus mutagenic effect is higher for T-705
than for ribavirin, since the impact of GTP depletion coupled to
UTP/GTP imbalance is reasonably less pronounced.
One intriguing question is the nature of the noninfectious vi-
rus particles that are abundantly produced inT-705-exposed virus
cultures.We exclude the possibility that these are defective viruses
containing large internal deletions (54), since these would have
been detected in our deep-sequencing analysis. A plausible hy-
pothesis is that these are incomplete particles lacking one (or
more) of the eight genome segments (55), due to chain termina-
tion by T-705 and, hence, the impossibility to generate the pack-
aging signals at the 5= and 3= termini of the vRNA segment(s). The
hypothesis that T-705may enhance the production of incomplete
influenza virus virions is supported by our observation that the
virus readily returns to normal particle infectivity when T-705 is
omitted from the culture. We do not exclude an alternative (and
nonmutually exclusive) explanation that these nonviable particles
contain T-705 incorporated into their genomes. To assess whether
and to what degree T-705 can be incorporated into viral particles,
the use of radiolabeled compound would be required. Our RT-
qPCR and sequencing analyses probably ignored many (if not all)
vRNA segments with incorporated T-705, since the RT reaction is
likely slowed or terminated when faced with a T-705 molecule
incorporated into the vRNA template.
To summarize (Fig. 8), T-705 and ribavirin have dual yet dis-
tinct effects on viral RNA synthesis. Both agents give complete
inhibition at high concentrations. At lower concentrations, T-705
induces abundant production of noninfectious particles. Pro-
longed exposure to low concentrations of T-705 or ribavirin
causes viral mutagenesis; this effect is 2-fold higher for T-705 than
ribavirin and leads to reduced viral fitness associated with a wide
range of amino acid substitutions.Whereas T-705 functions at the
level of the viral polymerase, ribavirin acts by GTP depletion via
IMPDH inhibition; this explains why the therapeutic index of
T-705 by far exceeds that of ribavirin. Whether the mutagenic
effect of these agents on influenza virus also plays in the clinical
context is at this stage speculative; recent in vivo data obtained in a
mouse influenza model (28) suggest that this may be possible for
T-705. Quasispecies formation of hepatitis C virus following ex-
posure to ribavirin has been observed in cell culture-based studies
but not during long-term treatment of patients (56). In the case of
influenza virus, T-705- or ribavirin-induced noninfectious or
mutant viruses may be even less likely to appear, considering that
influenza treatment is much shorter and that nonviable virus par-
ticles are probably cleared by the patient’s immune response.
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